[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"NICHD Pelvic Floor Disorders Network\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":102},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100552987","trial-of-transurethral-bulking-agent-injection-versus-single-incision-sling-for-stress-urinary-incontinence-100552987",false,"NCT06480227","Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence","A Randomized Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence","BASIS","Inclusion Criteria:\n\n* Women ≥ 21 years\n* For \\> 3 months, bothersome SUI (response of somewhat, moderately, or quite a bit) without UUI or stress-predominant MUI. For those with equal bother of UUI and SUI, clinician determination that SUI is more severe\u002Fsignificant than UUI is required.\n* A positive cough stress test on standardized non-invasive testing or urodynamic SUI within the past 18 months.\n* Normal PVR \\\u003C 150 mL\n* Candidate for either study procedure as determined by treating surgeon\n* Available for up to 3 years.\n* Agrees to randomization.\n\nExclusion Criteria:\n\n* Anterior\u002Fapical vaginal prolapse beyond the hymen (\\>0 on POPQ)\n* Urge-predominant mixed UI despite stable therapy\n* Advanced UUI\u002FOAB 3rd line therapy treatment within 1 year of enrollment.\n* Planned hysterectomy, urethral or anterior\u002Fapical surgeries s requiring general anesthesia at the time of SUI treatment, during the last 6 months, or planned within the next 12 months.\n* Malignancy or history of radiation of the pelvis\n* Pregnant, post-partum, breast feeding or plans for pregnancy within 1 year\n* Incomplete emptying (PVR \\> 150mL)\n* Prior anti-incontinence procedure\n* Neurogenic bladder\n* Unwilling to continue current UUI treatment until completion of primary outcome at 12 months\n* Prior adverse reaction to synthetic mesh or urethral bulking material\n* Chronic bladder or pelvic pain conditions (e.g., Interstitial cystitis, painful bladder syndrome, fibromyalgia, chronic pelvic pain, etc.)\n* Active treatment for SUI with a pessary. For those using a pessary or other SUI support device, a 3-week washout period should occur prior to assessing baseline measures.","FEMALE","21 Years",{"count":20,"type":21},358,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a multicentered, double-blind, randomized controlled, surgical trial of 358 women with inadequate symptom relief of stress urinary incontinence (SUI) or stress predominant mixed urinary incontinence (MUI) after conservative care.\n\nThe Primary Aim is to determine the comparative effectiveness (as defined by \"much\" or \"very much\" better on PGI-I) of transurethral bulking agent (TBA) \\[for 1 or 2 injections in 12 months\\] vs. single-incision sling (SIS) 12 months after treatment intervention in women with predominant stress urinary incontinence (SUI).",[27,28,29],"Stress Urinary Incontinence","Urinary Incontinence","Mixed Urinary Incontinence",[28,31,32,33],"Pelvic Floor Disorders","Single Incision Sling","Transurethral Bulking Agent","RECRUITING","2026-06-04",{"date":37,"type":38},"2026-06-08","ACTUAL",{"date":40,"type":38},"2024-08-28",{"date":42,"type":21},"2030-12-31",{"name":44,"class":45},"NICHD Pelvic Floor Disorders Network","NETWORK",7,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":46},"100609702","accelerometer-measured-early-recovery-after-prolapse-surgery-100609702","NCT07218016","Accelerometer Measured Early Recovery After Prolapse Surgery","AccelERate","Inclusion Criteria:\n\n* Subject has provided written informed consent\n* Ambulatory women undergoing laparoscopic, robotic, or vaginal reconstructive or obliterative surgery for apical prolapse\n* POP-Q \\>= Stage III\n* Willing to participate in a postoperative exercise regimen\n* Able to read and consent in English or Spanish\n* Willing and able to wear an accelerometer prior to and after surgery (including agreeing to the terms of service), use an electronic data capture software, and record daily events\n* Willing and able to install and use study-related smartphone app(s)\n* Anticipated hospital discharge \\\u003C= postoperative day 1\n\nExclusion Criteria:\n\n* Inability or unwillingness to adhere to the exercise intervention\n* Contraindication to medium-intensity exercise\n* Comorbidities preventing physical activity\n* Planned abdominal approach with laparotomy","18 Years","99 Years",{"count":57,"type":21},288,[24],"The AccelERate study will evaluate the physical recovery of patients who have undergone Pelvic Organ Prolapse (POP) surgery. This will be evaluated via a self-reported recovery questionnaire completed daily. Participants will wear an accelerometer device on their non-dominant wrist and be given either routine or exercise-focused postoperative instructions. The primary outcome will be a comparison of the number of days needed to reach self-reported \"mostly recovered\" status between randomly assigned instruction groups.",[61,62,63,64],"Pelvic Organ Prolapse","Pelvic Organ Prolapse (POP)","Pelvic Organ Prolapse Vaginal Surgery","Pelvic Organ Prolapse, Patient Education",[66,62,67,68],"accelerometer","Post-operative Recovery","recovery activities","2026-04-24",{"date":71,"type":38},"2026-04-27",{"date":73,"type":38},"2025-10-02",{"date":75,"type":21},"2028-03-31",{"name":44,"class":45},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":46},"100547683","training-for-urinary-leakage-improvement-after-pregnancy-100547683","NCT06411158","Training for Urinary Leakage Improvement After Pregnancy","TULIP","Inclusion Criteria:\n\n1. ≥18yo primiparous patient s\u002Fp singleton vaginal delivery (\\>32 weeks), approximately 6wk postpartum\n2. At increased risk of sustained pelvic floor disorders, as defined by\n\n   1. neonate ≥3.5kg, and\u002For\n   2. operative delivery (i.e., forceps or vacuum-assisted vaginal delivery), and\u002For\n   3. ≥2nd-degree perineal laceration\n3. Symptomatic, bothersome UI as defined by a score of ≥6 on the ICIQ-SF.\n\nExclusion Criteria:\n\n1. Inability to complete study assessments or procedures, per clinician judgment, or not available for 6mo postpartum follow-up\n2. Stillbirth or significant maternal or neonatal illness\n3. Non-English or non-Spanish speaking\n4. Perineal wound breakdown or cloaca observed on exam\n5. Severe pain with assessments of PFM integrity and\u002For strength\u002Ffunction\n6. Already engaged (since delivery) in in-person physical therapy for strengthening of the pelvic floor\n7. Unwilling or unable to upload and use external smartphone app(s)",{"count":85,"type":21},216,[24],"This is a multi-center, randomized single-blind nonsurgical trial conducted in approximately 216 primiparous postpartum women at high risk for prolonged\u002Fsustained pelvic floor disorders with symptomatic, bothersome urinary incontinence (UI) amenable to nonsurgical treatment.\n\nTULIP is a 3-Arm trial with two active interventions (Arms 1 and 2) and a Patient Education control arm (Arm 3). Arm 1 consists of pelvic floor muscle training (PFMT). Arm 2 uses a home biofeedback device (leva®).\n\nThe primary outcome will be assessed at 6 months postpartum by blinded outcomes assessors, and follow-up will continue until 12 months postpartum.",[28,89],"Delivery Complication",[28,31,91,92,93],"Physical Therapy","Biofeedback","Anal Incontinence","2025-12-29",{"date":96,"type":38},"2025-12-31",{"date":98,"type":38},"2024-11-12",{"date":100,"type":21},"2027-11-12",{"name":44,"class":45},""]